摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,3-dimethyl-1-(naphthalen-1-yl)butan-2-one | 132855-24-4

中文名称
——
中文别名
——
英文名称
3,3-dimethyl-1-(naphthalen-1-yl)butan-2-one
英文别名
3,3-dimethyl-1-naphthalen-1-ylbutan-2-one
3,3-dimethyl-1-(naphthalen-1-yl)butan-2-one化学式
CAS
132855-24-4
化学式
C16H18O
mdl
——
分子量
226.318
InChiKey
RIZNUXVSKZMCDI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:798ac73c49538abcc0f663da2f237e9d
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Nickel-Catalyzed α-Arylation of Ketones with Phenol Derivatives
    作者:Ryosuke Takise、Kei Muto、Junichiro Yamaguchi、Kenichiro Itami
    DOI:10.1002/anie.201403823
    日期:2014.6.23
    The nickel‐catalyzed α‐arylation of ketones with readily available phenol derivatives (esters and carbamates) provides access to useful α‐arylketones. For this transformation, 3,4‐bis(dicyclohexylphosphino)thiophene (dcypt) was identified as a new, enabling, air‐stable ligand for this transformation. The intermediate of an assumed CO oxidative addition was isolated and characterized by X‐ray crystal‐structure
    镍与容易获得的苯酚衍生物(酯和氨基甲酸酯)催化的α-芳基化反应提供了有用的α-芳基酮的获得途径。对于此转化,3,4-双(二环己基膦基)噻吩(dcypt)被确定为该转化的一种新的,稳定的,空气稳定的配体。假定C的中间 ö氧化加成物分离和表征通过X射线晶体结构分析。
  • LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX
    申请人:NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    公开号:US20160074853A1
    公开(公告)日:2016-03-17
    An object of the present invention is to provide a method for directly performing arylation (particularly α-arylation) of carbonyl or thiocarbonyl compounds using a more inexpensive phenol derivative and nickel catalyst. Another object of the present invention is to provide a novel nickel catalyst that can be used in this method, and a novel ligand of the nickel catalyst. The novel compounds of the present invention are a compound having a diphosphine skeleton in which a five- or six-membered heterocyclic ring is substituted with two dialkylphosphines and/or dicycloalkylphosphines, or a salt thereof, and a compound having the diphosphine skeleton that is bound to nickel. Moreover, coupling reaction of a carbonyl compound and a phenol derivative can be advanced in the presence of a nickel compound having a monodentate or bidentate dialkylphosphine and/or dicycloalkylphosphine skeleton.
    本发明的一个目的是提供一种使用更便宜的酚衍生物和镍催化剂直接进行羟基化(尤其是α-羟基化)的醛或硫醛化合物的方法。本发明的另一个目的是提供一种可以用于该方法的新型镍催化剂,以及镍催化剂的新型配体。本发明的新化合物是一种含有二膦骨架的化合物,其中五元或六元杂环环被两个二烷基膦和/或二环烷基膦取代,或其盐,以及与镍结合的具有二膦骨架的化合物。此外,在存在具有一膦或二膦二烷基膦和/或二环烷基膦骨架的镍化合物的情况下,可以促进醛化合物和酚衍生物的偶联反应。
  • The effect of substituents in SRNl reactions. Some synthetic applications
    作者:Joseph F. Bunnett、Eric Mitchel、Carlo Galli
    DOI:10.1016/s0040-4020(01)97188-1
    日期:1985.1
    Most of the ortho effects are slight, but there is evidence that large ortho substituents hinder attachment of the phosphite more than the enolate nucleophile. The methoxy and diethoxyphosphoryl substituents, when para to the site of substitution, respectively favour and disfavour the phosphite with respect to the enolate ion. SRNl reactions of ortho-substituted halobenzenes are, for some substituents
    几个邻位取代的iodobenzenes被允许反应,经由S RN升机构,用亚磷酸二乙酯和离子烯醇频哪酮离子的混合物。从产物组成数据,推算出两种亲核试剂的相对反应性。它们代表与芳基自由基中间体连接的相对反应性。大多数邻位作用是轻微的,但是有证据表明,较大的邻位取代基比亚油酸酯亲核试剂更阻碍亚磷酸酯的附着。当在取代位置的对位时,甲氧基和二乙氧基磷酰基取代基相对于烯醇酸根离子分别有利和不利于亚磷酸酯。小号RN对于某些取代基,邻位取代的卤代苯的反应是随后进行的其他反应,这些反应提供了具有合成意义的产物。
  • Determination of Rate Constants for the Reaction of Aryl Radicals with Enolate Ions
    作者:Alfonso Annunziata、Carlo Galli、Manuela Marinelli、Tullia Pau
    DOI:10.1002/1099-0690(200104)2001:7<1323::aid-ejoc1323>3.0.co;2-c
    日期:2001.4
    Similarly, the reactions of radical clock precursors 3 or 8 with the enolate ion failed. However, investigation of the distribution of 9-anthracenyl (11•) or 1-naphthyl (12•) radicals between two competing reactions, namely combination with a nucleophile and H abstraction from the solvent (Me2SO), was successful and eventually enabled us to find the kY values for the addition of the enolate ion to these
    发现通过中间苯基型自由基在系链双键处的分子内攻击,o-(ω-烯基)芳基自由基的闭环速率 (kC) 为 4.2 × 108 s-1(对于 1• ) 和 7.6×107 s−1(对于 8•),都是 6-exo-trig 过程,9.6 × 109 s−1 对于 3• 的 5-exo-trig 过程。这些自由基的 kC 速率常数根据已知的 H 原子提取速率 (kH) 进行校准。自由基钟前体 1 与阴离子 PhS− 和 (EtO)2PO− 在 25 °C 下在 Me2SO 中的光刺激 SRN1 反应提供了这些亲核试剂 (kY) 添加到中间体 1•(3.2 × 108 和 2.5 × 109M−1)的速率s−1,分别)。相比之下,酮烯醇化物离子与前体 1 的类似反应没有进行预期的 SRN1 过程;相反,有利于消除反应。相似地,自由基时钟前体 3 或 8 与烯醇化物离子的反应失败。然而,研究 9-蒽基 (11•)
  • Alpha-4 beta-1 integrin ligands for imaging and therapy
    申请人:Lam S. Kit
    公开号:US20060019900A1
    公开(公告)日:2006-01-26
    The present invention provides α 4 β 1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
    本发明提供了α4β1整合素配体,该配体具有高结合亲和力、特异性和稳定性。该配体包括具有n个独立选择的氨基酸的肽,其中至少一个氨基酸是非天然氨基酸或D-氨基酸,n为3到20的整数。提供了用于治疗癌症、炎症性疾病和自身免疫疾病的配体给药方法。还提供了用于在受试者中成像肿瘤、器官或组织的配体给药方法。
查看更多